About: Azilsartan medoxomil     Goto   Sponge   Distinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug of Azilsartan marketed as "Edarbi" by Takeda. Azilsartan medoxomil has so far been shown to be superior to olmesartan and valsartan in lowering blood pressure. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Jones JD, Jackson SH, Agboton C, Martin TS: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22346296 # Lanier G, Sankholkar K, Aronow WS: Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin-Angiotensin-Aldosterone System Antagonists. Am J Ther. 2012 Sep 12. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22975662 # Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43. doi: 10.2147/VHRM.S22595. Epub 2012 Feb 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22399858 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
http://linked.open...drugbank/halfLife
  • The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations. (en)
http://linked.open...ugbank/indication
  • Treatment of hypertension (alone or as an adjunct). (en)
sameAs
Title
  • Azilsartan medoxomil (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Azilsartan medoxomil blocks the angiotensin II type 1 receptor preventing angiotensin II from binding and causing vasoconstriction. Azilsartan's ability to remain tightly bound to AT1 receptors for very long periods after drug washout is among its most unusual features. (en)
http://linked.open...outeOfElimination
  • Renal clearance is 2.3 L/minute. (en)
http://linked.open.../drugbank/synonym
  • Azilsartan kamedoxomil (en)
  • Azilsartan (en)
  • Azilsartan medoxomilo (en)
  • Azilsartanum medoxomilum (en)
  • Edarbi (en)
http://linked.open...drugbank/toxicity
  • Hypotension and diarrhea are most common. (en)
http://linked.open...umeOfDistribution
  • Azilsartan medoxomil has a Vd of 16L. (en)
http://linked.open.../drug/hasAHFSCode
http://linked.open...k/foodInteraction
  • Food does not affect absorption or bioavailibity. (en)
  • Nutrition/Herbal interaction (en)
http://linked.open.../drugbank/mixture
http://linked.open...nk/proteinBinding
  • Azilsartan medoxomil is 99% plasma protein bound. (en)
http://linked.open...ynthesisReference
  • Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T: Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. 1996 Dec 20;39(26):5228-35. (en)
foaf:page
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...logy/drugbank/pKa
http://linked.open...l/drug/hasATCCode
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open...ugbank/absorption
  • Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan in the GI tract. The presence of food does not affect oral absorption of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum plasma concentrations are reached in 1.5 to 3 hours. (en)
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 147403-03-0 (en)
http://linked.open...drugbank/category
  • (en)
http://linked.open...rugbank/clearance
  • Fecal elimination accounts for 55%, urine excretion 42%, and unchanged drug 15%. (en)
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...ank/Melting-Point
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...strongest-acidic-
http://linked.open...-strongest-basic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software